Veracyte Stock News

Veracyte (VCYT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 156.2% to close at $0.2608 on Thursday after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions relat

VCYT exceeded investors' expectations, coupling solid revenue growth with improved profitability. Unique international exposure offers revenue tailwinds as Europe accelerates gene diagnostic testing a

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. Acutus

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. Virax Biolabs Group Limited (NASDAQ: VRAX) surged 34% to $2.25 after the company announced the distribution of a RSV-I

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Thursday. The Federal Reserve, on Wednesday, raised interest rates by 75 bps. The Dow traded down 0.50% t

Veracyte (VCYT) delivered earnings and revenue surprises of 50% and 12.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Veracyte (VCYT) delivered earnings and revenue surprises of 50% and 12.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Veracyte, Inc. (NASDAQ:VCYT ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 AM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Re

ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. Click to see the firm's trades for Q3 2022.

SOUTH SAN FRANCISCO, Calif.

Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.

Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate

Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.